1DH1 and TIBSOVO® (ivosidenib)
Phase 3 trial sees significant benefit as end point is achieved - The company plans to submit a supplemental new drug application for TIBSOVO® in previously treated IDH1 mutant cholangiocarcinoma by the end of 2019.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
